In this Immunotherapy perspective, learn more about advances and possible future developments in adoptive immunotherapy.
Chimeric antigen receptor (CAR) T cells have outstanding therapeutic potential for treating blood cancers. The prospects for this technology have accelerated basic research, clinical translation and Big Pharma’s investment in the field of T-cell therapeutics. In this perspective from Immunotherapy, Chungyong Han and Byoung S Kwon discuss advances in adoptive immunotherapy and review CAR T-cell studies that focus on CAR constructs, target antigens and T-cell phenotypes.
Han C, Kwon BS. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective. Immunotherapy. 10(3), 221—234 (2018)